Comparative Cost Per Response for four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-To-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis
May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.1323
https://www.valueinhealthjournal.com/article/S1098-3015(18)31626-7/fulltext
Section Title :
Section Order :
576
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31626-7&doi=10.1016/j.jval.2018.04.1323